Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSavills Regulatory News (SVS)

Share Price Information for Savills (SVS)

Share Price is delayed by 15 minutes
Get Live Data
808.00    -10.00 (-1.22%)
Bid:
811.00
Ask:
813.00
Spread: 2.00 (0.247%)
Market Cap: £1.12b
SVS Live PriceLast checked at - London Stock Exchange

Intraday Savills Share Chart

Director/PDMR Shareholding

18 Jun 2021 11:12

RNS Number : 3959C
Savills PLC
18 June 2021
 

SAVILLS PLC (THE 'COMPANY')

NOTIFICATION OF INTERESTS OF DIRECTORS/ PDMRS

 

Grant of Share Awards

 

The Company announces that on 17 June 2021 the grant of the share based element of 2020 profit share awards has been made under the Savills Deferred Share Bonus Plan to Directors and other persons discharging managerial responsibilities ('PDMR') as follows:-

 

Director/ PDMR

Number of shares subject to the Savills Deferred Share Bonus Plan awarded to the Director/ PDMR on17 June 2021

Resulting beneficial interest under the Savills Deferred Share Bonus Plan and Savills Deferred Share Plan

Mark Ridley (Director)

23,926

149,045

Simon Shaw (Director)

17,747

140,750

Simon Hope (PDMR)

2,129

13,230

Alex Jeffrey (PDMR)

22,033

158,272

Chris Lee (PDMR)

11,073

37,045

Raymond Lee (PDMR)

33,983

33,983

Christian Mancini (PDMR)

5,251

23,165

Mitchell Rudin (PDMR)

8,239

78,366

James Sparrow (PDMR)

19,410

84,245

The above awards have a Deferred Period of three years and are subject to rolled-up dividend shares whereby the number of shares awarded will be increased on the vesting date to reflect final and interim dividends declared during the Deferred Period.

* The resulting beneficial interest for Alex Jeffrey (CEO, Savills Investment Management) includes an award over 136,239 shares made on 31 October 2019 under the Savills Deferred Share Plan whereby 28% of the award vests subject to continued employment in October 2022, with 72% vesting subject to the satisfaction of performance criteria relating to the financial performance of Savills Investment Management over the years 2020 to 2022.

 

The Company announces that on 17 June 2021 the grant of a share award under The Schedule to The Savills Deferred Share Plan to a PDMR based in the United States of America as follows:-

 

PDMR

Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on17 June 2021

Resulting beneficial interest under the Savills Deferred Share Plan

David Lipson (PDMR)

21,374

56,326

20% of the above award will vest on 18 April 2022, being the anniversary of the programme's original inception, and then 20% on each of the subsequent four anniversaries of that date subject to continued employment and satisfaction of performance criteria relating to gross billings. The award is subject to rolled-up dividend shares whereby the number of shares awarded will be increased on the vesting dates to reflect final and interim dividends declared during the Deferred Periods.

 

The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.

1.

Details of the Director/ PDMR

 

(a)

Name

1. Mark Ridley

2. Simon Shaw

3. Simon Hope

4. Alex Jeffrey

5. Chris Lee

6. Raymond Lee

7. Christian Mancini

8. Mitchell Rudin

9. James Sparrow

10. David Lipson

 

2.

Reason for the notification

 

(a)

Position/ status

1. Group Chief Executive/ Director

2. Group Chief Financial Officer/ Director

3. Global Head of Capital Markets/ PDMR

4. Chief Executive Officer - Savills Investment Management/ PDMR

5. Group Legal Director and Company Secretary/ PDMR

6. Chief Executive - Hong Kong, Macau and Greater China/ PDMR

7. Chief Executive Officer - Asia Pacific (ex-Greater China)/ PDMR

8. Chairman and CEO - Savills North America/ PDMR

9. Chief Executive Officer UK & EMEA/ PDMR

10. President - Savills North America/ PDMR

 

(b)

Initial notification/ Amendment

 

Initial notification

3.

Details of the issuer

 

(a)

Name

Savills plc

 

(b)

LEI

213800WXICGMBWHTA933

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

(a)

Description of the Financial Instrument

 

Awards over Savills plc Ordinary Shares of 2.5p each

(b)

Identification code of the Financial Instrument

 

GB00B135BJ46

(c)

Nature of the transaction

 

Grant of awards over Ordinary Shares in accordance with the Company's Deferred Share Bonus Plan and Deferred Share Plan

 

(d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

£nil per share

 

1. 23,926

2. 17,747

3. 2,129

4. 22,033

5. 11,073

6. 33,983

7. 5,251

8. 8,239

9. 19,410

10. 21,374

 

(e)

Aggregated information

 

- Aggregated volume

- Price

 

N/A

 

 

(f)

Date of the transaction

 

17 June 2021

(g)

Place of the transaction

 

Outside a trading venue

 

Name of contact and telephone number for queries:

Chris Lee

Group Legal Director & Company Secretary

020 3107 5444

 

18 June 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHMZGMVGRMGMZM
Date   Source Headline
2nd Dec 202410:00 amRNSTotal Voting Rights
26th Nov 20243:34 pmRNSHolding(s) in Company
22nd Nov 20242:00 pmRNSAdditional Listing
15th Nov 20242:58 pmRNSHolding(s) in Company
14th Nov 20241:53 pmRNSHolding(s) in Company
13th Nov 20241:47 pmRNSHolding(s) in Company
12th Nov 20242:51 pmRNSDirector/PDMR Shareholding
12th Nov 20242:48 pmRNSHolding(s) in Company
11th Nov 20242:25 pmRNSHolding(s) in Company
1st Nov 202411:00 amRNSTotal Voting Rights
14th Oct 20249:52 amRNSDirector/PDMR Shareholding
4th Oct 20242:00 pmRNSAdditional Listing
1st Oct 202411:00 amRNSTotal Voting Rights
18th Sep 20242:43 pmRNSDirector Declaration
16th Sep 20243:50 pmRNSDirector Declaration
12th Sep 20241:47 pmRNSDirector/PDMR Shareholding
2nd Sep 202411:00 amRNSTotal Voting Rights
29th Aug 20242:24 pmRNSDirector/PDMR Shareholding
15th Aug 202411:00 amRNSBlock listing Interim Review
13th Aug 20243:17 pmRNSDirector/PDMR Shareholding
8th Aug 20247:00 amRNSHalf-year Report
1st Aug 202411:00 amRNSTotal Voting Rights
30th Jul 20242:11 pmRNSHolding(s) in Company
22nd Jul 20242:36 pmRNSBlock listing Interim Review
11th Jul 20244:26 pmRNSDirector/PDMR Shareholding
1st Jul 20249:27 amRNSTotal Voting Rights
20th Jun 202410:36 amRNSDirector/PDMR Shareholding
13th Jun 20241:37 pmRNSDirector/PDMR Shareholding
11th Jun 20244:42 pmRNSDirector/PDMR Shareholding
7th Jun 20244:01 pmRNSDirector/PDMR Shareholding
4th Jun 20242:43 pmRNSDirector/PDMR Shareholding
3rd Jun 202411:00 amRNSTotal Voting Rights
23rd May 20242:21 pmRNSDirector/PDMR Shareholding
17th May 20243:44 pmRNSDirector/PDMR Shareholding
15th May 20243:06 pmRNSResult of AGM
15th May 202410:02 amRNSAGM Statement
14th May 20248:00 amRNSDirector/PDMR Shareholding
2nd May 20248:28 amRNSTotal Voting Rights
26th Apr 20242:13 pmRNSDirector/PDMR Shareholding
26th Apr 202411:21 amRNSDirector Declaration
15th Apr 20243:42 pmRNSDirector/PDMR Shareholding
12th Apr 20245:12 pmRNSDirector/PDMR Shareholding
8th Apr 20243:47 pmRNSAnnual Report and AGM Notice
21st Mar 20248:17 amRNSDirector/PDMR Shareholding
19th Mar 20245:11 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSNon-Executive Director Appointment
14th Mar 20247:00 amRNSFinal Results
13th Mar 20241:37 pmRNSDirector/PDMR Shareholding
15th Feb 202410:00 amRNSBlock listing Interim Review
13th Feb 20246:07 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.